COMMUNIQUÉS West-GlobeNewswire

TG Therapeutics, Inc. Announces Oral Presentation of Umbralisib plus Ruxolitinib in Patients with Myelofibrosis at the 23rd Congress of the European Hematology Association

15/06/2018 - 14:13

Data demonstrates that the addition of umbralisib to ruxolitinib can induce responses in patients with sub-optimal response to ruxolitinib single agent NEW YORK, June 15, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ( [...]

Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association

15/06/2018 - 14:00

NEW YORK and LONDON, June 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan [...]

Insmed Announces FDA Advisory Committee Meeting to Review ALIS as a treatment for NTM Lung Disease Caused by MAC

15/06/2018 - 14:00

Meeting planned for August 7, 2018 BRIDGEWATER, N.J., June 15, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, [...]

Extendicare Announces June 2018 Dividend of C$0.04 per Share

15/06/2018 - 14:00

MARKHAM, Ontario, June 15, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share [...]

Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association

15/06/2018 - 14:00

CG-806 Continues to Demonstrate Superior Activity to Ibrutinib BTK Inhibitor STOCKHOLM, Sweden and SAN DIEGO, June 15, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the [...]

Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study

15/06/2018 - 13:50

Study completion and submission of 510(k) notification expected in Calendar Q3 2018 FRAMINGHAM, Mass., June 15, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of [...]

Summit Therapeutics to Present at the JMP Securities Life Sciences Conference

15/06/2018 - 13:01

Summit Therapeutics plc ("Summit", or the "Company") Summit Therapeutics to Present at the JMP Securities Life Sciences Conference Oxford, UK, and Cambridge, MA, US, 15 June 2018 - Summit Therapeutics plc (NASDAQ: SMMT [...]

AMAG Pharmaceuticals Announces Divestiture of Cord Blood Registry®

15/06/2018 - 13:00

Transaction Underscores AMAG’s Focus on Clinical Development and Commercialization of Pharmaceuticals Company Intends to Use the Majority of Proceeds to Pay off High-Yield Debt WALTHAM, Mass., June 15, 2018 (GLOBE [...]

Aclaris Therapeutics Expands Leadership Team, Appointing Dr. David Gordon as Chief Medical Officer

15/06/2018 - 13:00

Former Deputy Office Director at the FDA, Elaine Morefield, PhD, also joins Aclaris WAYNE, Pa., June 15, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company [...]

Summit Therapeutics to Present at the JMP Securities Life Sciences Conference

15/06/2018 - 13:00

Oxford, June 15, 2018 (GLOBE NEWSWIRE) -- Oxford, UK, and Cambridge, MA, US, 15 June 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Glyn Edwards, Chief Executive Officer, will present at the JMP [...]

Athenex Announces Appointment to Board of Directors

15/06/2018 - 13:00

BUFFALO, N.Y., June 15, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]

Trillium Therapeutics Completes Amendment to SIRPaFc License Agreement

15/06/2018 - 13:00

Trillium to issue C$3 million of common shares to retire sublicense revenue sharing provision TORONTO, June 15, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno- [...]

PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company

15/06/2018 - 12:26

Oslo (Norway), 15 June 2018 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company [...]

Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Association (EHA)

15/06/2018 - 11:30

Consistently High Responses in Patients with an EZH2 Activating Mutation Durable Clinical Responses and Progression-Free Survival Observed in Patients With or Without an EZH2 Activating Mutation Company to Host Investor [...]

Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018

15/06/2018 - 11:30

3-month Phase 2 data continue to show SEL-212 (SVP-Rapamycin + pegsiticase) may present a superior product profile over current FDA-approved chronic severe gout therapy with serum uric acid (SUA) control of 81%, reduced [...]

Affimed Announces Updated Data of AFM13 in Combination with Keytruda® (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA

15/06/2018 - 11:00

Best response data from 18 patients confirms favorable safety profile and overall response rate of 89% Management to host conference call today at 8:30 a.m. ET / 2:30 p.m. CET to discuss future development plans for [...]

Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life

15/06/2018 - 08:41

Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of patients reported fatigue as [...]

Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer

15/06/2018 - 08:36

Comparison of Jakavi ® (ruxolitinib) vs. best available therapy presented at EHA suggests reduced risk of death in patients with inadequately controlled polycythemia vera (PV)[1] Additional data at EHA suggests earlier [...]

GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease (SCD) at 23rd European Hematology Association (EHA) Congress

15/06/2018 - 08:30

Data from Four Additional Posters to be Presented, Including New Pharmacokinetic Data from HOPE-KIDS 1 Study Supporting Use of Weight-based Dosing Strategy for Voxelotor Clinical Trials in Children SOUTH SAN FRANCISCO, [...]